[Reuters] – Biogen Idec Inc said on Wednesday its new, high-profile oral multiple sclerosis drug Tecfidera had sales of $398 million in the fourth quarter, easily exceeding estimates for a third successive quarter and keeping it on track to top $1 billion in its first year on the market. Biogen said underlying patient demand for the drug represented about $348 million of the U.S. sales, still ahead of analysts’ consensus expectations of about $335 million. Biogen … [visit site to read more]
- Company Update – Biogen Idec Inc. (NASDAQ:BIIB) – Biogen wins protection for MS drug Tecfidera in Europe
- Market Update on Biogen Idec Inc. (NASDAQ:BIIB) – Biogen’s new MS drug tops sales expectations, earnings rise
- 3M Company (NYSE:MMM) – 3M Co profit rises 6 pct as sales grow
